Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age

Name: Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age
Published: 2007
License: Public Domain

GlaxoSmithKline · 2007

ClinicalTrials.gov · Datasets · License: Public Domain · 2007

Open Source ↗

adults cervical-cancer comparative-study human-papillomavirus-hpv humans immunogenicity infections safety

infections, papillomavirus, papillomavirus vaccines, vaccines, cervical cancer, immunogenicity, humans, safety, viral infections, human papillomavirus (hpv), comparative study, human papillomavirus vaccine, adults

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 1008537
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.